Updates In Myeloid Disorders: How To Calculate The Blast In Myelodysplastic Syndrome, New Treatments, Safety, & Ongoing Trials
Aref Al-Kali MD Of The Mayo Clinic Discusses Updates In Myeloid Disorders: How To Calculate The Blast In Myelodysplastic Syndrome, New Treatments, Safety, & Ongoing Trials. Author: Annual-Meeting Added: 06/12/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 13, 2019 Category: Cancer & Oncology Source Type: podcasts

Personalized Prognoses for Myelodysplastic Syndromes Using Machine Learning
Aziz Nazha MD of Cleveland Clinic discusses using Personalized Prognoses for Myelodysplastic Syndromes Using Machine Learning at ASH 2018 Author: ASHReport Added: 12/14/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 14, 2018 Category: Cancer & Oncology Source Type: podcasts

Personalized Model for Allogeneic Hematopoietic Stem Cell Patients with Myelodysplastic Syndromes
Aziz Nazha MD of Cleveland Clinic discusses the overview of his study of A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplast... Author: ASHReport Added: 12/14/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 14, 2018 Category: Cancer & Oncology Source Type: podcasts

Molecular background studies to aid diagnosis and treatment of MDS
With the the field of molecular diagnostics rapidly advancing, the demand for prognostic and diagnostic molecular information on myelodysplastic syndrome (MDS) is also increasing. Here, Torsten Haferl... Author: VJHemOnc Added: 09/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 28, 2018 Category: Cancer & Oncology Source Type: podcasts

Identifying genetic mutations for diagnosing MDS
Knowledge of the molecular background of myelodysplastic syndrome (MDS) has been greatly advanced by developments in techniques such as next-generation sequencing (NGS) and ChIP-sequencing. Professor ... Author: VJHemOnc Added: 09/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 28, 2018 Category: Cancer & Oncology Source Type: podcasts

The role of EZH2 mutations in MDS
EZH2 mutations are associated with a poor prognosis in myelodysplastic syndromes (MDS). In this video, recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Rashmi... Author: VJHemOnc Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Is there hope for treating TP53-mutated MDS?
In this interview, Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, speaks about TP53-mutated myelodysplastic syndromes (MDS) and the results of the Phase Ib/II cl... Author: VJHemOnc Added: 08/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Hypomethylating agents for low risk MDS
Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses extending the use of hypomethylating agents from patients with high risk myelodysplastic syndromes (MDS) to individ... Author: VJHemOnc Added: 08/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2018 Category: Cancer & Oncology Source Type: podcasts

IDH inhibitors for AML and MDS
There has been an influx of novel therapies within the field of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Here, Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, Bu... Author: VJHemOnc Added: 08/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2018 Category: Cancer & Oncology Source Type: podcasts

A new set of treatment options for low-risk MDS
Treatments for low-risk myelodysplastic syndromes (MDS) cannot cure the disease, but rather aim to improve quality of life, reduce complications and increase overall survival by reducing cytopenia. In... Author: VJHemOnc Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

A worldwide Phase III trial treating AML with pracinostat
Pracinostat has been shown to be an effective therapy for treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in several Phase I and Phase II studies. Here, Guillermo Garcia-Mane... Author: VJHemOnc Added: 07/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 5, 2018 Category: Cancer & Oncology Source Type: podcasts

Update MDS and Nonmalignant Heme
Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks about updates on Myelodysplastic syndrome and nonmalignant hemetology at MOASCs Spotlight On Hematology in Huntington Beach. Author: moasc Added: 02/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 2, 2018 Category: Cancer & Oncology Source Type: podcasts

Highlights from MDS and Nonmalignant Hematology - New drugs for MDS: Rigosertib, Luspatercept, Ibrutnib
Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks about the highlights from Myelodysplastic Syndrome (MDS) and nonmalignant hematology and also new drugs for MDS: Rigosertib, Luspater... Author: moasc Added: 02/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 1, 2018 Category: Cancer & Oncology Source Type: podcasts

Personalized Prediction Model for Myelodysplastic Syndromes - Certain mutations predict non-malignant conditions
Sudipto Mukherjee, MD from Cleveland Clinics discusses personalized prediction model for Myelodysplastic Syndromes and certain mutations predict non-malignant conditions at the 2017 American Society o... Author: ASHReport Added: 01/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 27, 2018 Category: Cancer & Oncology Source Type: podcasts

Predicting Survival Myelodysplastic Syndrome - Using the Random Survival Forest Algorithm
Aziz Nazha, MD from the Cleveland Clinic discusses predicting Survival Myelodysplastic Syndrome and using the Random Survival Forest Algorithm at the 2017 American Society of Hematology. Author: ASHReport Added: 01/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 11, 2018 Category: Cancer & Oncology Source Type: podcasts

Algorithm Picks Relevant Variables Variables help predict survivability with myelodysplastic syndromes
Aziz Nazha, MD from the Cleveland Clinic discusses algorithm picks relevant variables and variables help predict survivability with myelodysplastic syndromes at the 2017 American Society of Hematology... Author: ASHReport Added: 01/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 11, 2018 Category: Cancer & Oncology Source Type: podcasts

Promising results in MDS for ASTX727, an oral decitabine and cytidine deaminase inhibitor agent
Decitabine, a DNA methyltransferase (DNMT) inhibitor, which is given to patients with myelodysplastic syndromes (MDS), is classically administered intravenously. Now, ASTX727, an oral combination of d... Author: VJHemOnc Added: 01/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 8, 2018 Category: Cancer & Oncology Source Type: podcasts

Pracinostat for AML update: follow-up analysis and Phase III trial
Pracinostat is a histone deacetylase (HDAC) inhibitor that has demonstrated very promising efficacy in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Here, Guillermo Garcia-Manero, ... Author: VJHemOnc Added: 01/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 8, 2018 Category: Cancer & Oncology Source Type: podcasts

MDS and MPNs update from ASH 2017
In this exciting interview, Claire Harrison, MD, DM, FRCP, FRCPath, of Guy's and St Thomas' NHS Foundation Trust, London, UK, discusses the data on myelodysplastic syndromes (MDS) and myeloproliferati... Author: VJHemOnc Added: 12/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 19, 2017 Category: Cancer & Oncology Source Type: podcasts

Oral azacitidine maintenance therapy for post-transplant AML
Relapse remains the main obstacle for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after allogeneic stem cell transplantation and novel therapeutic strategies are urg... Author: VJHemOnc Added: 12/18/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 18, 2017 Category: Cancer & Oncology Source Type: podcasts

New salvage treatment for AML/MDS after allogeneic transplant: the VIOLA trial
The outcome for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) after allogeneic stem cell transplantation remains poor. In this interview, Charles Craddock, CBE, FRCP (U... Author: VJHemOnc Added: 12/18/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 18, 2017 Category: Cancer & Oncology Source Type: podcasts

The future of AML and MDS diagnosis and treatment
There is currently a conundrum regarding the differentiation of acute myeloid leukemia and myelodysplastic syndromes. In this interview, Stphane de Botton, MD, PhD of the Gustave Roussy Institute, Vi... Author: VJHemOnc Added: 12/07/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 7, 2017 Category: Cancer & Oncology Source Type: podcasts

Developing an understanding of disease progression in MDS and AML
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) increasingly appear to be influenced by genetic features, with new research attempting to provide a clearer understanding of how geneti... Author: VJHemOnc Added: 11/30/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 30, 2017 Category: Cancer & Oncology Source Type: podcasts

Topical challenges in the management of ET
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Ji Schwarz discusses challenges in the management of essential thrombocythemia.... Author: imedex Added: 10/30/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2017 Category: Cancer & Oncology Source Type: podcasts

Biology and therapy of eosinophilic neoplasms
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Andreas Reiter discusses the biology and therapy of eosinophilic neoplasms.Earn... Author: imedex Added: 10/30/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2017 Category: Cancer & Oncology Source Type: podcasts

Mechanisms of bone marrow fibrosis in Myelofibrosis
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Jean Luc Villeval discusses the mechanisms of bone marrow fibrosis in patients with... Author: imedex Added: 10/30/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2017 Category: Cancer & Oncology Source Type: podcasts

New mouse models of MPN
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Radek C. Skoda discusses new mouse models of myeloproliferative neoplasms (MPN).... Author: imedex Added: 10/30/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2017 Category: Cancer & Oncology Source Type: podcasts

Role of immune system in MDS pathogenesis
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Astrid Olsnes Kittang discusses the role of the immune system in the pathogenesis o... Author: imedex Added: 10/30/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2017 Category: Cancer & Oncology Source Type: podcasts

Advances in understanding of MDS microenvironment
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Carmen Aanei elucidates recent advances in the understanding of the myelodysplastic... Author: imedex Added: 10/30/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2017 Category: Cancer & Oncology Source Type: podcasts

Genetic basis of MDS
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Luca Malcovti discusses the genetic basis of myelodysplastic syndromes (MDS).Ea... Author: imedex Added: 10/30/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2017 Category: Cancer & Oncology Source Type: podcasts

Experimental therapeutics in MPN: Where is the field going?
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Alessandro M. Vannucchi discusses the future of experimental therapeutics for the t... Author: imedex Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

Clonal evolution of MPN to accelerated or blastic phase: Therapeutic insights
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Srdan Verstovsek discusses therapeutic insights into the clonal evolution of myelop... Author: imedex Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

My approach to MF management
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Claire Harrison outlines her approach to the management of myelofibrosis.Earn C... Author: imedex Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

MF marrow morphology: Key takeaways from WHO 2016 diagnostic update
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Hans Michael Kvasnicka discsuses myelofibrosis marrow morphology and the key takeaw... Author: imedex Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

Experimental therapeutics in MDS New opportunities
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Jaroslav Cermak discusses new opportunities resulting from the utilization of exper... Author: imedex Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

Optimal use of lenalidomide as therapy for MDS
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Aristoteles Giagounidis discusses the optimal use of lanalidomide as therapy for my... Author: imedex Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

Iron chelation therapy for MDS
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Norbert Gattermann discusses iron chelation therapy for myelodysplastic syndromes (... Author: imedex Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

My approach to MDS management
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Eva Hellstrm-Lindberg outlines her approach to the management of myelodysplastic s... Author: imedex Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

Hypocellular MDS vs. aplastic anemia - Diagnosis and therapy
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Austin G. Kulasekararaj discusses the difference between hypocellular MDS and aplas... Author: imedex Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

My view on current and future use of JAK inhibitors for ET, PV, and MF
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Martin Griesshammer outlines his view on the current and future use of JAK inhibito... Author: imedex Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

Key Insights in MPN & MDS
In this discussion, recorded during the 2017 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 4-5, 2017 in Philadelphia, the Congress co-chairs highlight the key poi... Author: imedex Added: 08/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 23, 2017 Category: Cancer & Oncology Source Type: podcasts

Key Insights: A European Perspective on MPN & amp; MDS
In this discussion, the co-chairs of the European Focus on Myeloproliferative Neoplasms & Myelodysplastic Syndromes 2017 highlight the key points presented during the meeting, with the aim of shar... Author: imedex Added: 05/05/2017 (Source: Oncology Tube)
Source: Oncology Tube - May 5, 2017 Category: Cancer & Oncology Source Type: podcasts

PodMed – Week of February 13, 2017
This week’s topics include sickle cell trait and HbA1c, carcinogen levels and e-cigarettes, mutations and myelodysplastic syndrome, and kids ingesting pet medicines. Program notes: 0:33 Kids eating medicines intended for pets 1:34 Retrospective poison center data 2;28 Must have appropriate medication dispensing 2:40 Sickle cell trait and hemoglobin A1c 3:41 In diabetes the higher your […] (Source: Johns Hopkins Medicine Weekly Health News)
Source: Johns Hopkins Medicine Weekly Health News - February 10, 2017 Category: Consumer Health News Authors: Elizabeth Tracey Johns Hopkins Medicine Tags: All Podcasts Cancer Pediatrics PodMed Smoking Source Type: podcasts

Genetic Alterations Predict Outcomes in MDS
Navneet Majhail, MD of Cleveland Clinic, gives an overview of Abstract 69: Genetic Alterations Predict Outcomes in Patients with Myelodysplastic Syndrome Receiving Allogeneic Hematopoietic Stem Cell T... Author: ASHReport Added: 12/12/2016 (Source: Oncology Tube)
Source: Oncology Tube - December 12, 2016 Category: Cancer & Oncology Source Type: podcasts

Jamile M. Shammo, MD, FASCP, FACP - Precision Care for Myelodysplastic Syndromes: Listening to Patient Voices, Exploring New Science
Precision Care for Myelodysplastic Syndromes: Listening to Patient Voices, Exploring New Science (Source: PeerView CME/CE Audio Podcast - Oncology)
Source: PeerView CME/CE Audio Podcast - Oncology - December 10, 2016 Category: Cancer & Oncology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts

Update on Long-acting Interferons for MPN
In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA, Dr. Richard T. Silver provides and update on long-acting... Author: imedex Added: 10/05/2016 (Source: Oncology Tube)
Source: Oncology Tube - October 5, 2016 Category: Cancer & Oncology Source Type: podcasts

Splanchnic Vein Thrombosis and MPN: Diagnosis and Therapy
In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA, Dr. Michael Kroll discusses the diagnosis and treatment ... Author: imedex Added: 10/05/2016 (Source: Oncology Tube)
Source: Oncology Tube - October 5, 2016 Category: Cancer & Oncology Source Type: podcasts

The WHO Updated Diagnostic Criteria for ET, PV & MF
In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA, Dr. Mark Heaney discusses the updated WHO diagnostic cri... Author: imedex Added: 10/05/2016 (Source: Oncology Tube)
Source: Oncology Tube - October 5, 2016 Category: Cancer & Oncology Source Type: podcasts

Biology and Therapy of Eosinophilic MPNs
In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA, Dr. Jason R. Gotlib discusses the biology and therapy of... Author: imedex Added: 10/05/2016 (Source: Oncology Tube)
Source: Oncology Tube - October 5, 2016 Category: Cancer & Oncology Source Type: podcasts

Interplay of Somatic and Germline Variants in MPN
In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA, Dr. Stephen T. Oh discusses the interplay of somatic and... Author: imedex Added: 10/05/2016 (Source: Oncology Tube)
Source: Oncology Tube - October 5, 2016 Category: Cancer & Oncology Source Type: podcasts